Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNC | P24863 | 12/20 | 0.47 |
| ▸ | CDK8 | P49336 | 12/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10138523 | 0.89 | CCNC (0.46) | CCNCCDK8ALDH1A1HRH3 | |
| SCHEMBL10138453 | 0.87 | CCNC (0.41) | CCNCCDK8ALDH1A1SCN9A | |
| SCHEMBL10138530 | 0.84 | ALDH1A1 (0.42) | CCNCCDK8ALDH1A1HRH3 | |
| SCHEMBL10138395 | 0.84 | CCNC (0.53) | CCNCCDK8ALDH1A1HRH3TBK1 | |
| SCHEMBL10138413 | 0.82 | CCNC (0.52) | CCNCCDK8ALDH1A1HRH3 | |
| SCHEMBL578607 | 0.80 | CCNC (0.59) | CCNCCDK8LMNA | |
| SCHEMBL10138507 | 0.78 | CCNC (0.48) | CCNCCDK8ALDH1A1HRH3 | |
| SCHEMBL578375 | 0.78 | CCNC (0.48) | CCNCCDK8 | |
| SCHEMBL10138535 | 0.78 | CCNC (0.54) | CCNCCDK8 | |
| SCHEMBL10138514 | 0.78 | CCNC (0.52) | CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-8410273-B2 | Cyclic compound having substituted phenyl group | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-02-16 | — | — | US | disclosed |
| WO-2010116915-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | 第一三共株式会社 (JP) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040936-A1 | CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP | BMP2, BMP4, BMP6 | CCNC 1592/4885CDK8 2959/4885ALDH1A1 2092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.